Abstract Library

#2299 Expanding the WHO 2017 Classification to Gastrointestinal Tumors: Real-World Data from the R-GETNE Registry

Introduction: The update of the WHO 2017 classification of pancreatic neuroendocrine tumors (NETs) introduces the distinction between NET & NEC G3, based on histological differentiation. However, little is known about the possibility of extending this concept to non-pancreatic NETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Castaño A, Capdevila J, Benavent M,

Keywords: WHO classification, NET G3, NEC G3, non-pancreatic NET, poorly differentiated,

#869 Phase 1 Expansion Study of an Oral TORC1/TORC2 Kinase Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)

Introduction: Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223 is an ATP-competitive inhibitor of the mTOR kinase, inhibiting both TORC1 and TORC2.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Meyer T, Mahipal A, Bendell J, Nemunaitis J, Mita M,

Keywords: TORC-1 CC-223,

#322 Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment

Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pham C, E. B, C. C, J. G, F. B,

Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,